Skip to content

The Efficacy of Melatonin in the Burning Mouth Syndrome

Study of the Efficacy of Melatonin in the Burning Mouth Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03788733
Acronym
BMS
Enrollment
80
Registered
2018-12-28
Start date
2018-12-14
Completion date
2019-12-14
Last updated
2018-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorders, Circadian Rhythm

Keywords

Burning mouth syndrome,, melatonin, pain, sleep

Brief summary

Burning mouth ( BMS) syndrome is the oral disorder characterized by an intraoral burning sensation for which no medical or dental cause can be found. The Headache Classification Committee of the International Headache Society (IHS) defines (BMS) as an ''intraoral burning or dysaesthetic sensation, recurring daily for more than 2 hours per day over more than 3 months, without clinically evident causative lesions''. (BMS) is a common, chronic problem that has a negative impact on quality of life. A wide variety of medications have been proposed for treating (BMS) both topical and systemic. Unfortunately, no treatment seems to offer assured results. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep Melatonin also may help sleep disturbances associated with (BMS) ; however, this remains to be proven.

Detailed description

The purpose of this study is to establish whether melatonin can aid in reducing pain improve sleep quality in (BMS)

Interventions

1 time a day for 8 weeks

1 time a day for 8 weeks

Sponsors

Universidad de Murcia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Intraoral burning or dysaesthetic sensation, recurring daily for more than 2 hours per day over more than 3 months, without clinically evident causative lesions

Exclusion criteria

* Previous or current therapy with melatonin * Allergy or hypersensitivity to melatonin * Less than 18 years old. * Pregnant

Design outcomes

Primary

MeasureTime frameDescription
Sleep Questionnaireday 0 .The PSQI total score ranges from 0 to 21 with 0 being marvelous sleep and 21 being horrid sleep. The difference score, reported below, is the total score after at least 8 weeks of treatment. A negative score means that the sleepThe Pittsburgh Sleep Quality Index (PSQI)

Secondary

MeasureTime frameDescription
Oral Painday 0 .Pain was scored using a Visual Analogue Scale (VAS) (with a score of 1-10: 0 = no pain, 10 = extreme pain)Visual Analogue Scale (VAS)
Questionnaire ORAL Quality of lifeday 0 The instrument consists of 14 items that explore different aspects of oral function and quality of life. The score ranges from 0 to 70, with higher scores corresponding to poorer oral quality of life.Questionnaire OHIP 14 Oral quality of life

Countries

Spain

Contacts

Primary ContactLopez-Jornet Pia, PhD
majornet@um.es639473308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026